[go: up one dir, main page]

DK3271358T3 - Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor - Google Patents

Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor Download PDF

Info

Publication number
DK3271358T3
DK3271358T3 DK16713022.8T DK16713022T DK3271358T3 DK 3271358 T3 DK3271358 T3 DK 3271358T3 DK 16713022 T DK16713022 T DK 16713022T DK 3271358 T3 DK3271358 T3 DK 3271358T3
Authority
DK
Denmark
Prior art keywords
receptor
muscarin
spirocyclic compounds
agonists
receptor agonists
Prior art date
Application number
DK16713022.8T
Other languages
English (en)
Inventor
Miles Stuart Congreve
Giles Albert Brown
Benjamin Gerald Tehan
Mark Pickworth
Julie Elaine Cansfield
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Application granted granted Critical
Publication of DK3271358T3 publication Critical patent/DK3271358T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK16713022.8T 2015-03-19 2016-03-21 Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor DK3271358T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504675.8A GB201504675D0 (en) 2015-03-19 2015-03-19 Pharmaceutical compounds
PCT/GB2016/050771 WO2016147011A1 (en) 2015-03-19 2016-03-21 Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor

Publications (1)

Publication Number Publication Date
DK3271358T3 true DK3271358T3 (da) 2021-02-08

Family

ID=53052080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16713022.8T DK3271358T3 (da) 2015-03-19 2016-03-21 Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor

Country Status (10)

Country Link
US (1) US10167284B2 (da)
EP (1) EP3271358B1 (da)
JP (1) JP6675415B2 (da)
CN (1) CN107406449B (da)
AU (1) AU2016231951B9 (da)
CA (1) CA2979009C (da)
DK (1) DK3271358T3 (da)
ES (1) ES2852753T3 (da)
GB (1) GB201504675D0 (da)
WO (1) WO2016147011A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3768669B1 (en) * 2018-03-23 2023-01-25 Pfizer Inc. Piperazine azaspiro derivaves
GB201810239D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20221454A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
US11548865B2 (en) 2019-10-09 2023-01-10 Novartis Ag 2-azaspiro[3.4]octane derivatives as M4 agonists
EP4126825A1 (en) * 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Aminocyclobutanes as monoacylglycerol lipase modulators
KR20220158060A (ko) * 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아릴 피페리딘
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025210042A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer
WO2025210041A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Bicyclic benzylamido pyridine derivatives as sos1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032489A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
RU2008130094A (ru) * 2005-12-22 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
CN102361876B (zh) * 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物
ES2619829T3 (es) * 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
SG11201501620QA (en) * 2012-09-18 2015-04-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor agonists
HRP20181499T1 (hr) 2014-02-06 2018-11-30 Heptares Therapeutics Limited Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2016231951A1 (en) 2017-09-28
US10167284B2 (en) 2019-01-01
CA2979009A1 (en) 2016-09-22
EP3271358B1 (en) 2020-11-18
WO2016147011A1 (en) 2016-09-22
JP2018508562A (ja) 2018-03-29
CN107406449A (zh) 2017-11-28
EP3271358A1 (en) 2018-01-24
AU2016231951B2 (en) 2020-04-09
ES2852753T3 (es) 2021-09-14
GB201504675D0 (en) 2015-05-06
JP6675415B2 (ja) 2020-04-01
CN107406449B (zh) 2020-11-10
HK1248218A1 (en) 2018-10-12
US20180072727A1 (en) 2018-03-15
CA2979009C (en) 2023-09-12
AU2016231951B9 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
DK3271358T3 (da) Spirocykliske forbindelser som agonister af muscarin m1-receptor og/eller m4-receptor
DK3368060T3 (da) Glugacon-receptor-agonister
DK3370828T3 (da) Oximforbindelse som agonister af muscarin m1- og/eller m4- receptoren
DK3256853T3 (da) Forudsigelse af t-celleepitoper, der er egnede til vaccination
IL259947B (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3331863T3 (da) Hidtil ukendte forbindelser som ror-gamma-modulatorer
DK3386500T3 (da) Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
DK3322967T3 (da) Viskositetsmålinger
DK3265459T3 (da) Amidforbindelser som 5-ht4-receptoragonister
DK3160266T3 (da) Sukkererstatningssammensætning
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3347360T3 (da) Forbindelser, som er anvendelige til inhibering af ror-gamma-t
DK3265057T3 (da) Topisk formulering
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
DK3347349T3 (da) Fluorindolderivater som muskarin m1-receptor-positive allosteriske modulatorer
DK3204380T3 (da) Hidtil ukendte aminopyridinforbindelser, der er anvendelige som hæmmere af proteinprenylering
DK3357520T3 (da) Viskoelastisk sammensætning
IL263884A (en) Ethynyl derivatives
DK3277928T3 (da) Rotor til vingeanordning
EP3653672A4 (en) THERMALLY CROSS-LINKABLE COMPOSITION
DK3250549T3 (da) Cyclopropylmethanaminer som selektive 5-HT(2C)-receptoragonister